IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity

被引：0
|
作者：
Khurshed, Mohammed
Aarnoudse, Niels
Hulsbos, Renske
Hira, Vashendriya V. V.
van Laarhoven, Hanneke W. M.
Wilmink, Johanna W.
Molenaar, Remco J.
van Noorden, Cornelis J.
机构：
来源：
FASEB JOURNAL | 2019年 / 33卷
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
250.8
引用
收藏
页数：5
相关论文
共 50 条
  • [21] ESTABLISHMENT AND CHARACTERIZATION OF IDH1-MUTANT HYPERMUTATED GLIOMA CELL LINES
    Jones, Lindsey
    Mazor, Tali
    Grimmer, Matthew
    Najac, Chloe
    Mukherjee, Joydeep
    Chow, Tracy
    Pieper, Russel
    Ronen, Sabrina
    Phillips, Joanna J.
    Chang, Susan
    Costello, Joseph
    NEURO-ONCOLOGY, 2017, 19 : 259 - 259
  • [22] REAL-WORLD OUTCOMES AMONG HIGH GRADE IDH1-MUTANT GLIOMA PATIENTS TREATED WITH AN IDH INHIBITOR
    Ziv, Michal Nisnboym
    Patel, Mallika P.
    Minor, Maria
    Johnson, Margaret O.
    Batich, Kristen
    Low, Justin
    Shoaf, Madison L.
    Khasraw, Mustafa
    Desjardins, Annick
    Friedman, Henry S.
    Ashley, David M.
    Peters, Katherine B.
    NEURO-ONCOLOGY, 2024, 26
  • [23] Comparative survey of mitochondrial ultrastructure in IDH1-mutant astrocytoma and IDH1-wildtype glioblastoma (GBM)
    Maraqah, Haitham H.
    Abu-Asab, Mones S.
    Lee, Han Sung
    Aboud, Orwa
    ULTRASTRUCTURAL PATHOLOGY, 2023, 47 (02) : 116 - 121
  • [24] Loss of FBXW7 Correlates with Increased IDH1 Expression in Glioma and Enhances IDH1-Mutant Cancer Cell Sensitivity to Radiation
    Yang, Zhuo
    Hu, Nan
    Wang, Weiwei
    Hu, Weihua
    Zhou, Shaolong
    Shi, Jianxiang
    Li, Minghe
    Jing, Zhou
    Chen, Chao
    Zhang, Xuyang
    Yang, Ruyi
    Fu, Xudong
    Wang, Xinjun
    CANCER RESEARCH, 2022, 82 (03) : 497 - 509
  • [25] Protocol to establish a genetically engineered mouse model of IDH1-mutant astrocytoma
    Shi, Diana D.
    Lee, Joyce H.
    Wang, Adam C.
    Khanal, Januka
    Gao, Wenhua
    Kaelin Jr, William G.
    Mcbrayer, Samuel K.
    STAR PROTOCOLS, 2023, 4 (02):
  • [26] Tibsovo® (ivosidenib) - first targeted Therapy for IDH1-mutant Tumor Diseases
    Sonnet, Miriam
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (09)
  • [27] IDH2 compensates for IDH1 mutation to maintain cell survival under hypoxic conditions in IDH1-mutant tumor cells
    Zhang, Yao
    Lv, Weifeng
    Li, Qi
    Wang, Qinhao
    Ru, Yi
    Xiong, Xin
    Yan, Fengqi
    Pan, Tao
    Lin, Wei
    Li, Xia
    MOLECULAR MEDICINE REPORTS, 2019, 20 (02) : 1893 - 1900
  • [28] An in vivo patient-derived model of endogenous IDH1-mutant glioma
    Luchman, H. Artee
    Stechishin, Owen D.
    Dang, N. Ha
    Blough, Michael D.
    Chesnelong, Charles
    Kelly, John J.
    Nguyen, Stephanie A.
    Chan, Jennifer A.
    Weljie, Aalim M.
    Cairncross, J. Gregory
    Weiss, Samuel
    NEURO-ONCOLOGY, 2012, 14 (02) : 184 - 191
  • [29] Clinical Utility of Ivosidenib in the Treatment of IDH1-Mutant Cholangiocarcinoma: Evidence To Date
    Uson Junior, Pedro Luiz Serrano
    Borad, Mitesh J.
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 1025 - 1031
  • [30] Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses
    Wen Cheng
    Xiufang Ren
    Chuanbao Zhang
    Jinquan Cai
    Sheng Han
    Anhua Wu
    Molecular Neurobiology, 2017, 54 : 5996 - 6005
12345